Growth Metrics

Pfizer (PFE) Total Debt (2016 - 2026)

Pfizer has reported Total Debt over the past 18 years, most recently at $64.5 billion for Q1 2026.

  • Quarterly Total Debt rose 3.78% to $64.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $64.5 billion through Mar 2026, up 3.78% year-over-year, with the annual reading at $64.8 billion for FY2025, 1.33% up from the prior year.
  • Total Debt was $64.5 billion for Q1 2026 at Pfizer, down from $64.8 billion in the prior quarter.
  • Over five years, Total Debt peaked at $71.9 billion in Q4 2023 and troughed at $35.8 billion in Q4 2022.
  • The 5-year median for Total Debt is $63.6 billion (2023), against an average of $57.1 billion.
  • Year-over-year, Total Debt surged 100.64% in 2023 and then fell 11.05% in 2024.
  • A 5-year view of Total Debt shows it stood at $35.8 billion in 2022, then surged by 100.64% to $71.9 billion in 2023, then fell by 11.05% to $63.9 billion in 2024, then increased by 1.33% to $64.8 billion in 2025, then fell by 0.52% to $64.5 billion in 2026.
  • Per Business Quant, the three most recent readings for PFE's Total Debt are $64.5 billion (Q1 2026), $64.8 billion (Q4 2025), and $61.7 billion (Q3 2025).